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More isn’t better with acute  
low back pain treatment
Adding cyclobenzaprine or oxycodone/acetaminophen 
to naproxen for the treatment of acute low back pain 
does nothing more than increase adverse effects.
PRACTICE CHANGER
Consider treating patients with acute low 
back pain with naproxen only, as adding 
cyclobenzaprine or oxycodone/acetamino-
phen to scheduled naproxen does not im-
prove functional assessment at 7 days or 
3 months and increases adverse effects. 
STRENGTH OF RECOMMENDATION
B: Based on a high-quality, randomized con-
trolled trial (RCT).1
Friedman BW, Dym AA, Davitt M, et al. Naproxen with cyclobenza-
prine, oxycodone/acetaminophen, or placebo for treating acute low 
back pain: a randomized clinical trial. JAMA. 2015;314:1572-1580. 
ILLUSTRATIVE CASE
A 46-year-old man presents to the emergency 
department (ED) with low back pain (LBP) af-
ter helping a friend move a couch 3 days earli-
er. He denies any direct trauma to his back and 
describes the pain as a spasm in his lumbar 
spinal region with no radicular symptoms. The 
pain worsens with prolonged standing and 
any position changes. He has tried acetamino-
phen with no benefit. You diagnose a lumbar 
muscular strain. What medications should you 
prescribe to help relieve his LBP and improve 
his overall function?
Acute LBP prompts close to 2.7 mil-lion ED visits annually in the United States.2 It leads to persistent subjec-
tive impairment and continued analgesic 
usage at 7 days (impairment 70%, analgesic 
use 69%) and at 3 months (48% and 46%, re-
spectively) after ED discharge.3  Systematic 
reviews show that monotherapy with non-
steroidal anti-inflammatory drugs (NSAIDs) 
or muscle relaxers is better than placebo 
for relieving pain.4,5 A secondary analysis 
of patients (N=715) from a prospective co-
hort study showed that patients prescribed 
opiates for LBP had worse functioning 
at 6 months than those not prescribed 
opiates.6 
Monotherapy or combination therapy 
for LBP? That is the question 
Because medications used for LBP have 
different mechanisms of action, clinicians 
frequently combine them in an attempt to 
improve symptoms and function.2 Current 
evidence evaluating combination therapy 
demonstrates mixed results. A large RCT 
(N=867) showed that the combination of 
cyclobenzaprine and ibuprofen led to lower 
subjective pain intensity, but did not result 
in self-reported pain improvement (based 
on answers to the Patient Global Impression 
of Change and the Oswestry Disability In-
dex) than cyclobenzaprine alone. However, a 
small RCT (N=40) combining naproxen with 
cyclobenzaprine demonstrated improved 
LBP and spasm compared to naproxen 
alone.7,8 
This study sought to determine the bene-
fit of treating acute LBP with cyclobenzaprine 
or oxycodone/acetaminophen in combina-
tion with an NSAID compared to treatment 
with an NSAID alone.
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STUDY SUMMARY 
Adding second pain reliever to the 
NSAID provided no significant benefit 
This double-blinded RCT enrolled 323 adult 
patients presenting to an ED with ≤2 weeks of 
nontraumatic, nonradicular LBP, which was 
defined as pain between the lower border 
of the scapulae and the upper gluteal folds.1 
Participants had a score of >5 on the Roland-
Morris Disability Questionnaire (RMDQ), 
which measures functional impairment due 
to LBP (range: 0-24). Patients were excluded 
if they had radicular pain radiating below the 
gluteal folds, direct trauma to the back within 
the previous month, pain duration >2 weeks, 
or a recent history of >1 LBP episode per 
month. Patients with current or past chronic 
opioid use were also excluded.
All participants received 10 days’ worth 
of naproxen (500 mg twice daily). They 
were then randomized to receive either: 
oxycodone 5 mg/acetaminophen 325 mg; 
cyclobenzaprine 5 mg; or placebo, with in-
structions to take one to 2 tablets prn every 
8 hours for 10 days. They were told that if one 
tablet afforded sufficient relief, there was no 
need to take the second one, but if the first 
tablet did not provide relief within 30 min-
utes, they should take the second one. All pa-
tients also received a 10-minute educational 
session emphasizing the role of exercise, 
stretching, physical/massage therapy, and 
other non-pharmacologic interventions.
❚ The primary outcome was change 
in the RMDQ between ED discharge and a 
phone call 7 days later, with a 5-point im-
provement in the RMDQ considered clini-
cally significant. Secondary outcomes at 
7 days and 3 months after ED discharge in-
cluded subjective description of worst pain, 
frequency of LBP pain, frequency of analgesic 
use, satisfaction with treatment, median num-
ber of days to return to work and usual activi-
ties, need for follow-up health care visits, and 
opioid use. Investigators also asked about any 
adverse effects at 7 days and 3 months. 
At 7 days, patients randomized to 
naproxen plus placebo improved on reported 
RMDQ scores by a mean of 9.8 points, naprox-
en plus cyclobenzaprine by 10.1 points, and 
naproxen plus oxycodone/acetaminophen 
by 11.1 points. Between group differences 
in mean RMDQ changes showed no statisti-
cally significant differences with placebo vs 
cyclobenzaprine (0.3 points; P=.77), placebo 
vs oxycodone/acetaminophen (1.3 points; 
P=.28), and cyclobenzaprine vs oxycodone/
acetaminophen (0.9 points; P=.45). 
❚ Secondary outcomes. At 7 days, there 
was no significant difference between study 
groups in subjective pain assessment, fre-
quency of LBP, or use of as-needed medica-
tions in the prior 24 hours. There was also no 
difference in the median number of days to 
return to work or need for follow-up health 
care visits. In patients who took more than 
one dose of the study medication, those who 
took oxycodone/acetaminophen were more 
likely to describe their worst pain in the last 
24 hours as mild/none when compared to 
those taking placebo (number needed to 
treat [NNT]=6). About 72% of all subjects 
reported that they would choose the same 
treatment option again, with no difference 
between groups. At 3 months, no difference 
existed between groups in subjective pain as-
sessment, frequency of LBP, use of as-needed 
medications, or opioid use during the previ-
ous 72 hours.
❚ Adverse effects, including drowsiness, 
dizziness, stomach irritation, and nausea or 
vomiting, were more common in the oxyco-
done/acetaminophen and cyclobenzaprine 
treatment groups with a number needed to 
harm (NNH) of 5.3 and 7.8, respectively. 
WHAT’S NEW 
A second pain reliever adds nothing—
except adverse effects
This RCT found that adding cyclobenzaprine 
or oxycodone/acetaminophen to naproxen for 
the treatment of nontraumatic, nonradicular 
acute LBP did not significantly improve func-
tional assessment based on RMDQ scores or 
pain measures at 7 days or 3 months after the 
initial ED visit. It did, however, increase ad-
verse effects.
CAVEATS 
Researchers studied 
a specific subset of patients 
This study was performed in a single-site ur-
At 7 days,  
there was no  
significant  
difference  
between study 
groups in 
subjective pain  
assessment,  
frequency 
of low back  
pain, or use  
of as-needed  
medications 
in the previous  
24 hours. 
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ban ED and included a very specific subset 
of LBP patients, which limits the generaliz-
ability of the results. However, patients often 
present to their primary care physician with 
similar LBP complaints, and the results of 
the study should reasonably apply to other 
settings. 
The findings may not generalize to all 
NSAIDs, but there is no evidence to suggest 
that other NSAIDs would behave differently 
when combined with cyclobenzaprine or 
oxycodone/acetaminophen. In this inten-
tion-to-treat analysis, only about one-third 
of patients used the as-needed medication 
more than once daily; about another third of 
patients used the as-needed medication in-
termittently or never.
CHALLENGES TO IMPLEMENTATION
Patients may expect more  
than an NSAID for their back pain 
Patients expect to receive prescriptions, and 
physicians are inclined to write them if they 
believe they will help their patients. The evi-
dence, however, does not show a benefit to 
these prescription-only medications for low 
back pain.                 JFP
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